22157.jpg
Interstitial Lung Disease Pipeline Research 2024: Therapeutic Assessment of 120+ Pipeline Drugs
22. April 2024 09:28 ET | Research and Markets
Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "Interstitial Lung Disease - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides...
22157.jpg
Dry Powder Inhaler Devices Pipeline Analysis Report 2023: Stages of Development, Regulatory Pathways, Key Companies, Regional Insights
24. Januar 2024 04:59 ET | Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Dry Powder Inhaler Devices Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies" report has been added to ...
Global Pulmonary Arterial Hypertension Market
Global Pulmonary Arterial Hypertension Market Report 2023: Growing Prevalence of Lung Cancer and Other Lung Related Disorders Drives Sector
31. Mai 2023 07:23 ET | Research and Markets
Dublin, May 31, 2023 (GLOBE NEWSWIRE) -- The "Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and...
22157.jpg
Global Pulmonary Arterial Hypertension Market Report 2021: Market Leaders Opsumit and Uptravi are Being Investigated in Clinical Trials to Potentially Support Label Expansions to CTEPH
09. Juni 2021 08:58 ET | Research and Markets
Dublin, June 09, 2021 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension Market and Forecast Analysis to 2025" drug pipelines has been added to ResearchAndMarkets.com's offering. The report...
22157.jpg
Global Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast to 2030
24. November 2020 16:38 ET | Research and Markets
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's...
Cardiome and SteadyM
Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European Medicines Agency
06. Januar 2016 08:00 ET | SteadyMed Therapeutics
VANCOUVER, British Columbia and SAN RAMON, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME), (TSX:COM) and SteadyMed Ltd. (Nasdaq:STDY), today announced that the...
SteadyMed Receives O
SteadyMed Receives Orphan Drug Designation for Trevyent for the Treatment of Pulmonary Arterial Hypertension
05. Januar 2016 07:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed Demonstrat
SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin
07. Dezember 2015 07:00 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases...
SteadyMed to Report
SteadyMed to Report Recent Developments and Third Quarter 2015 Financial Results
05. November 2015 07:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases...
SteadyMed Announces
SteadyMed Announces Positive Clinical Study Results in Support of SMT-201 for the Treatment of Post Surgical Pain in the Home Setting
28. Oktober 2015 07:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...